57 results
S-8
EX-99.2
IMCR
Immunocore Holdings plc
12 Apr 21
Registration of securities for employees
4:02pm
, ill-health or disability (evidenced to the satisfaction of the Board);
(b) death;
(c) redundancy within the meaning of the Employment Rights Act 1996 … Holder attempts to do any of those things. But, the transfer of an Option to an Option Holder's Personal Representatives on the death of the Option
S-8
EX-99.1
IMCR
Immunocore Holdings plc
12 Apr 21
Registration of securities for employees
4:02pm
or disability (evidenced to the satisfaction of the Board);
(b) death;
(c) redundancy within the meaning of the Employment Rights Act 1996; or
(d) employment … to an Option Holder's Personal Representatives on the death of the Option Holder will not cause an Option to lapse.
Subject to rule 6.11, an Option shall
F-1/A
EX-10.3
IMCR
Immunocore Holdings plc
1 Feb 21
Registration statement (foreign) (amended)
6:21am
of such Award in the event of (i) such Participant’s death or Disability, (ii) a Corporate Event in which such Award is not assumed, continued … Participants or Awards (or portions thereof) uniformly.
(d) Termination of Status. The Administrator will determine how the disability, death
F-1/A
EX-10.18
IMCR
Immunocore Holdings plc
1 Feb 21
Registration statement (foreign) (amended)
6:21am
by Virtue of Death or Disability of Executive.
(a) In the event of Executive’s death while employed pursuant to this Agreement, all obligations … months and one day after Executive’s Separation from Service, and (b) the date of Executive’s death, the Company will: (i) pay to Executive a lump
20-F
2020 FY
EX-4.20
IMCR
Immunocore Holdings plc
25 Mar 21
Annual report (foreign)
7:01am
the date of grant of such Award in the event of (i) such Participant’s death or Disability, (ii) a Corporate Event in which such Award is not assumed … , death, retirement, authorized leave of absence or any other change or purported change in a Participant’s Service Provider status (including a change
S-8
EX-99.6
twmb38f
12 Apr 21
Registration of securities for employees
4:02pm
10-K
EX-10.12
wgq263s793h ycnc6
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
i6tme
28 Feb 24
Annual report
7:33am
S-8
EX-99.8
ik3dryrv15 lm01y
12 Apr 21
Registration of securities for employees
4:02pm
S-8
EX-99.5
omq mlknflzv5aub4p65
12 Apr 21
Registration of securities for employees
4:02pm
F-1/A
EX-3.1
1dcepd9v1 2u5b02n2
1 Feb 21
Registration statement (foreign) (amended)
6:21am
20-F
EX-1.1
x3mp dac1
25 Mar 21
Annual report (foreign)
7:01am
S-8
EX-99.3
84py82cyxp 81vh52djj
12 Apr 21
Registration of securities for employees
4:02pm
S-8
EX-99.4
pcyoju1txdnfx304a
12 Apr 21
Registration of securities for employees
4:02pm
6-K
c453ccm9s6u o5wm
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
40zx24vakc476
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
m8hszoa
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
8qwm5ximvxmrifub9
7 Dec 21
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:10pm
6-K
EX-99.1
q07e6bxvbwvd4et 4wh
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
PRE 14A
2zbpvkjq7fu8x2mw
2 Apr 24
Preliminary proxy
4:45pm